A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance-Reference-Cited by-同舟云学术

A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance

Published:2014-05-02 Issue:16 Volume:120 Page:2448-2456
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Pappo Alberto S.¹,Vassal Gilles²,Crowley John J.³,Bolejack Vanessa³,Hogendoorn Pancras C. W.⁴,Chugh Rashmi⁵,Ladanyi Marc⁶,Grippo Joseph F.⁷,Dall Georgina⁷,Staddon Arthur P.⁸,Chawla Sant P.⁹,Maki Robert G.¹⁰,Araujo Dejka M.¹¹,Geoerger Birgit¹²,Ganjoo Kristen¹³,Marina Neyssa¹⁴,Blay Jean-Yves¹⁵,Schuetze Scott M.¹⁶,Chow Warren A.¹⁷,Helman Lee J.¹⁸

Affiliation:

1. Solid Tumor Division; St. Jude Children's Research Hospital; Memphis Tennessee

2. Clinical and Translational Research; Gustave Roussy Institute; Villejuif France

3. Cancer Research and Biostatistics; Seattle Washington

4. Department of Pathology; Leiden University Medical Center; Leiden the Netherlands

5. Department of Internal Medicine; University of Michigan; Ann Arbor Michigan

6. Molecular Diagnostics Service; Memorial Sloan-Kettering Cancer Center; New York New York

7. Hoffmann-LaRoche; Basel Switzerland

8. Penn Hematology/Oncology; Abramson Cancer Center; Philadelphia Pennsylvania

9. Sarcoma Oncology Center; Santa Monica California

10. Department of Medicine; The Mount Sinai Medical Center; New York New York

11. MD Anderson Cancer Center; Department of Sarcoma Medical Oncology; Houston Texas

12. Pediatric Oncology; Gustave Roussy Institute; Villejuif France

13. Stanford University Medical Center; Stanford University School of Medicine; Stanford California

14. Department of Pediatrics, Stanford Cancer Center; Stanford University; Stanford California

15. Department of Medical Oncology; Centre Leon Berard; Lyon France

16. Department of Internal Medicine, Division of Hematology/Oncology; University of Michigan; Ann Arbor Michigan

17. Laboratory of Warren A. Chow; City of Hope National Medical Center; Duarte California

18. Molecular Oncology Section; National Institutes of Health; Bethesda Maryland

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.28728/fullpdf

Reference43 articles.

1. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study;Pappo;J Clin Oncol.,2005

2. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children's Oncology Group Study D9803;Arndt;J Clin Oncol.,2009

3. Howlader N Noone AM Krapcho M Garshell J Neyman N Altekruse SF Kosary CL Yu M Ruhl J Tatalovich Z Cho H Mariotto A Lewis DR Chen HS Feuer EJ Cronin KA SEER Cancer Statistics Review, 1975-2010, National Cancer Institute http://seer.cancer.gov/csr/1975_2010/

4. Risk of recurrence and survival after relapse in patients with Ewing sarcoma;Stahl;Pediatr Blood Cancer.,2011

5. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS);Kempf-Bielack;J Clin Oncol.,2005

Cited by 160 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted anti-angiogenesis therapy for advanced osteosarcoma;Frontiers in Oncology;2024-08-26

2. Genetic and molecular profiling in bone sarcomas: advancing personalized treatment approaches;InterConf;2024-08-19

3. Biological Sample Collection to Advance Research and Treatment: A Fight Osteosarcoma Through European Research and Euro Ewing Consortium Statement;Clinical Cancer Research;2024-06-13

4. The Capacity of Drug-Metabolising Enzymes in Modulating the Therapeutic Efficacy of Drugs to Treat Rhabdomyosarcoma;Cancers;2024-02-29

5. Dynamic network curvature analysis of gene expression reveals novel potential therapeutic targets in sarcoma;Scientific Reports;2024-01-04